Show simple item record

dc.contributor.authorRosa, M I
dc.contributor.authorMedeiros, Lidia Rosi
dc.contributor.authorBozzetti, M C
dc.contributor.authorFachel, J
dc.contributor.authorWendland, E
dc.contributor.authorZanini, R R
dc.contributor.authorMoraes, A B
dc.contributor.authorRosa, Daniela D
dc.date.accessioned2009-06-12T14:50:31Z
dc.date.available2009-06-12T14:50:31Z
dc.date.issued2007
dc.identifier.citationAccuracy of telomerase in cervical lesions: a systematic review., 17 (6):1205-14 Int. J. Gynecol. Canceren
dc.identifier.issn1048-891X
dc.identifier.pmid17506842
dc.identifier.doi10.1111/j.1525-1438.2007.00980.x
dc.identifier.urihttp://hdl.handle.net/10541/70380
dc.description.abstractThe detection of telomerase activity in cervix may provide information on cervical carcinogenesis and may be a marker to monitor cervical intraepithelial neoplasia transition. A quantitative systematic review was performed to estimate the accuracy of telomerase assay in cervical lesions. Studies that evaluated the telomerase test (telomerase repeated amplification protocol) for the diagnosis of cervix lesions and compared it to paraffin-embedded sections as the diagnostic standard were included. Ten studies were analyzed, which included 1069 women. The diagnostic odds ratio (DOR) for a positive telomerase test for low-grade squamous intraepithelial lesions (Lo-SIL) vs normal or benign lesions was 3.2 (95% CI, 1.9-5.6). The DOR for a positive telomerase test for high-grade squamous intraepithelial lesions (Hi-SIL) vs Lo-SIL, normal or benign lesions was 5.8 (95% CI, 3.1-10). For cervix cancer vs Hi-SIL, the DOR for a positive telomerase test was 8.1 (95% CI, 3.2-20.3) and for cervix cancer vs Lo-SIL, normal or benign lesions, it was 40.9 (95% CI, 18.2-91). Our data support the current hypothesis that telomerase may activate an early event in cervical carcinogenesis that could be associated with the initiation and progression of cervical lesions.
dc.language.isoenen
dc.subjectUterine Cervical Canceren
dc.subject.meshCervical Intraepithelial Neoplasia
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshOdds Ratio
dc.subject.meshSensitivity and Specificity
dc.subject.meshTelomerase
dc.subject.meshUterine Cervical Dysplasia
dc.subject.meshUterine Cervical Neoplasms
dc.titleAccuracy of telomerase in cervical lesions: a systematic review.en
dc.typeArticleen
dc.contributor.departmentPostgraduate Program in Epidemiology, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. mir@unesc.neten
dc.identifier.journalInternational Journal of Gynecological Canceren
html.description.abstractThe detection of telomerase activity in cervix may provide information on cervical carcinogenesis and may be a marker to monitor cervical intraepithelial neoplasia transition. A quantitative systematic review was performed to estimate the accuracy of telomerase assay in cervical lesions. Studies that evaluated the telomerase test (telomerase repeated amplification protocol) for the diagnosis of cervix lesions and compared it to paraffin-embedded sections as the diagnostic standard were included. Ten studies were analyzed, which included 1069 women. The diagnostic odds ratio (DOR) for a positive telomerase test for low-grade squamous intraepithelial lesions (Lo-SIL) vs normal or benign lesions was 3.2 (95% CI, 1.9-5.6). The DOR for a positive telomerase test for high-grade squamous intraepithelial lesions (Hi-SIL) vs Lo-SIL, normal or benign lesions was 5.8 (95% CI, 3.1-10). For cervix cancer vs Hi-SIL, the DOR for a positive telomerase test was 8.1 (95% CI, 3.2-20.3) and for cervix cancer vs Lo-SIL, normal or benign lesions, it was 40.9 (95% CI, 18.2-91). Our data support the current hypothesis that telomerase may activate an early event in cervical carcinogenesis that could be associated with the initiation and progression of cervical lesions.


This item appears in the following Collection(s)

Show simple item record